[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617168":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":11,"studyPopulation":11,"armGroups":29,"interventions":37,"overallOfficials":47,"centralContacts":52,"locations":61,"responsibleParty":96,"collaborators":11,"id":98,"slug":11,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":11,"eligibilityCriteria":103,"healthyVolunteers":99,"sex":104,"minAge":105,"maxAge":11,"enrollmentInfo":106,"targetDuration":11,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":77,"whyStopped":11,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Nuvectis Pharma, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13,17,20],{"measure":10,"description":11,"timeFrame":12},"Number of patients with treatment related adverse events and\u002For clinical laboratory abnormalities",null,"Up to 30 days post treatment",{"measure":14,"description":15,"timeFrame":16},"Objective response rate (ORR)","Best response of complete response (CR) or partial response (PR) per RECIST 1.1","Up to approximately 12 months",{"measure":18,"description":19,"timeFrame":16},"Duration of Response (DoR)","Confirmed CR or PR from the first documented response to the date of documented disease progression or death.",{"measure":21,"description":22,"timeFrame":16},"Disease Control Rate (DCR)","The proportion of patients with stable disease (SD), partial response (PR), or complete response (CR).",{"allocation":24,"interventionModel":25,"interventionModelDescription":11,"primaryPurpose":26,"observationalModel":11,"timePerspective":11,"maskingInfo":27},"NA","SEQUENTIAL","TREATMENT",{"masking":28,"maskingDescription":11,"whoMasked":11},"NONE",[30],{"label":31,"type":32,"description":33,"interventionNames":34},"Dose Exploration (Part 1)","EXPERIMENTAL","Escalating doses of NXP900 given with osimertinib",[35,36],"Drug: NXP900","Drug: Osimertinib",[38,43],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":11},"DRUG","NXP900","NXP900 is an orally administered inhibitor of SRC family kinases (SFK)",[31],{"type":39,"name":44,"description":45,"armGroupLabels":46,"otherNames":11},"Osimertinib","Osimertinib is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor",[31],[48],{"name":49,"affiliation":50,"role":51},"Zofia Piotrowska, MD, MHS","Massachusetts General Hospital","PRINCIPAL_INVESTIGATOR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":11,"email":57},"Erin Belshaw","CONTACT","12016278129","ebelshaw@nuvectis.com",{"name":59,"role":55,"phone":11,"phoneExt":11,"email":60},"Shay Shemesh","sshemesh@nuvectis.com",[62,75,86],{"facility":50,"status":63,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":11},"NOT_YET_RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-71.05977,42.35843,{"lat":73,"lon":72},{"facility":76,"status":77,"city":78,"state":79,"zip":80,"country":67,"countryCode":68,"cosmosGeoPoint":81,"geoPoint":85,"contacts":11},"NEXT Houston","RECRUITING","Houston","Texas","77054",{"type":70,"coordinates":82},[83,84],-95.36327,29.76328,{"lat":84,"lon":83},{"facility":87,"status":77,"city":88,"state":89,"zip":90,"country":67,"countryCode":68,"cosmosGeoPoint":91,"geoPoint":95,"contacts":11},"NEXT Virginia","Fairfax","Virginia","22031",{"type":70,"coordinates":92},[93,94],-77.30637,38.84622,{"lat":94,"lon":93},{"type":97,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100617168",false,"NCT07315113","Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer","A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Provide written informed consent.\n2. 18 years old or older.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.\n5. Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.\n\nExclusion Criteria:\n\n1. Subject's cancer has a known oncogenic driver alteration other than EGFR.\n2. Known EGFR mutations that cause resistance to osimertinib\n3. Known human epidermal growth factor receptor 2 (HER2) overexpression\n4. Any contraindications to treatment with osimertinib","ALL","18 Years",{"count":107,"type":108},18,"ESTIMATED","INTERVENTIONAL",[111],"PHASE1","This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)",[114,115],"EGFR Mutation Positive Non-small Cell Lung Cancer","EGFR Mutated Non-small Cell Lung Cancer Patients",[117,118,119,120,121,122,40,123],"EGFR","Epidermal growth factor receptor","NSCLC","non-small cell lung cancer","lung cancer","osimertinib","EGFR mutation","2025-12-18",{"date":126,"type":127},"2026-01-02","ACTUAL",{"date":124,"type":127},{"date":130,"type":108},"2027-06",{"name":5,"class":6},3]